Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule

Philippe Gatault(Centre Hospitalier Universitaire de Tours), Hervé Watier(Université de Tours), Cécile Bordes(Centre National de la Recherche Scientifique), Jean‐Michel Halimi(Centre Hospitalier Universitaire de Tours), Danielle Degenne(Université de Tours), Valérie Gouilleux‐Gruart(Université de Tours), Emmanuel Gyan(Inserm), Guillaume Brachet(Université de Tours), Christelle Barbet(Centre Hospitalier Régional Universitaire de Brest), Guillaume Récipon(Centre Hospitalier Universitaire de Tours), Alexandra Farrell(University of South Florida), David Ternant(Université de Tours)
mAbs
September 4, 2015
10.1080/19420862.2015.1086049
Cited by 87

Related Papers

Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines
|Blood|1996|315
Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association–European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*
|Nephrology Dialysis Transplantation|2017|228
Platelet CD154 Potentiates Interferon-α Secretion by Plasmacytoid Dendritic Cells in Systemic Lupus Erythematosus
|Science Translational Medicine|2010|219
Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population
|Kidney International|2000|191
Acute Renal Infarction
|Clinical Journal of the American Society of Nephrology|2012|176